Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

0.6972 -0.0028 (-0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Where Rallybio Stands With Analysts
 
Via Benzinga
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Expert Ratings for Rallybio
 
Via Benzinga
Rallybio: Q3 Earnings Insights
 
Via Benzinga
Where Rallybio Stands With Analysts
 
Via Benzinga
Analyst Ratings for Rallybio
 
Via Benzinga
Analyst Ratings for Rallybio
 
Via Benzinga
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
The Latest Analyst Ratings for Rallybio
 
Via Benzinga
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
From Rallybio Corporation
Via Business Wire
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
From Rallybio Corporation
Via Business Wire
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
From Rallybio Corporation
Via Business Wire
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
From Rallybio Corporation
Via Business Wire
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
Rallybio to Present at the Jefferies Healthcare Conference
From Rallybio Corporation
Via Business Wire
Rallybio Reports First Quarter 2023 Financial Results
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
From Rallybio Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
 
Via Benzinga
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.